Board of Directors

Dr. Alessandro RIVA, MD

Chairman and CEO

Dr. Riva has nearly 30 years’ experience in the Life Sciences industry.  He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and was previously CEO of Ichnos Sciences. Dr Riva was also Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma and led its integration and growth. He also managed the US and EU approvals of Yescarta, the first approved CAR-T cell therapy for adult patients with diffuse large B cell lymphoma.
Prior to Gilead, Dr. Riva was EVP, Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals.
Dr. Riva currently serves on the Boards of BeiGene and Century Therapeutics. He received his bachelor’s degree in medicine and surgery from the University of Milan and a certificate board in oncology and hematology from the same institution.


Committees: Member of the Strategy Committee and of the Clinical Development Committee

Chairman and CEO


Honorary Chairman

Alain Mérieux is Chairman of Institut Mérieux, a family holding company dedicated to medicine and public health worldwide.

In 1963, Alain Mérieux founded bioMérieux, an in vitro diagnostics company. From 1968 to 1994, he was Chairman of Institut Mérieux, which specialized in human and veterinary vaccines, before divesting the vaccine business. In 1994, he created a new bio-industrial pole in the field of diagnostics (bioMérieux), immunotherapy (Transgene and ABL), food safety and nutrition (Mérieux NutriSciences) and health investments (Mérieux Equity Partners).

He is President of Fondation Mérieux, an independent family foundation recognized as being in the public interest, which fights against infectious diseases in developing countries.

Alain Mérieux holds a PhD in Pharmacy. He served as an interna resident in the hospitals of Lyon and attended the PMD at Harvard Business School


Honorary Chairman



Philippe Archinard, Ph.D. has been Executive Vice-President, Technological Innovation and Scientific Partnerships at Institut Mérieux since 2021. He was Chairman and Chief Executive Officer of Transgene from 2010 to 2020; and CEO from 2004 to 2020. Previously he was CEO of Innogenetics from 2000 to 2010. From 1985 to 2000, he held various positions at bioMérieux, including management of bioMérieux, Inc. in the United States. He is a chemical engineer and has a Ph.D. in biochemistry from the University of Lyon, and supplemented his education with a management program at the Harvard Business School. He is Chairman of the Institut des Recherches Technologiques (IRT) BIOASTER.

Philippe Archinard, Ph.D., has been a Director of the Company since 2004.

Committees: Member of the Strategy Committee and Member of the Clinical Development Committee


Michel Baguenault de Puchesse

Michel Baguenault


Michel Baguenault de Puchesse has been CEO of Institut Mérieux since January 2020. Prior to this position, Michel held several positions within the Institut Mérieux group: Executive Vice President of Institut Mérieux (2009 – 2011), Corporate Vice President, HR and Communication of bioMérieux (2011 – 2016), Secretary General of bioMérieux, in charge of Human Resources, Communication, Audit – Risks & Compliance, and Protocol (2016 – 2020).
Before joining Institut Mérieux, he was Financial Strategy Advisor at Financière Meeschaert, from 1996 to 2004, and Head of Development at Banque Martin Maurel in Lyon, from 2004 to 2008. Michel Baguenault de Puchesse is a graduate from EM LYON Business School and holds a Law degree. Within the Institut Mérieux Group, Michel Baguenault de Puchesse is a board member of Institut Mérieux, Mérieux NutriSciences, Fondation Christophe & Rodolphe Mérieux, and non-executive President of Mérieux Equity Partners.

Outside the Group, he is board member of CIC Lyonnaise de Banque, Descours & Cabaud SA, Mutuelles AXA, Siparex / Sigefi, Fondation Solidarités by Crédit Agricole. He also joined the supervisory board of Unibel.




Director, Chairman of the Strategy Committee

Jean-Luc Bélingard was Chairman and Chief Executive Officer of bioMérieux S.A from 2010 to 2017. He graduated from the Ecole des Hautes Etudes Commerciales (HEC) of Paris (1971) and holds a Master of Business Administration (MBA) from Cornell University, US (1974). Since then, he has held management positions at Merck, Sharp and Dohme (1974-1983), Roche France (“Président du Directoire”, 1983-1990), F. Hoffman-La Roche Ltd. (Member of the Executive Committee, 1990-1998), Roche Diagnostics, Basel (Chief Executive Officer, 1990-1998), bioMérieux-Pierre Fabre (Chief Executive Officer, 1999-2001), Ipsen Group (Chairman and Chief Executive Officer, 2002-2010).

Jean-Luc Bélingard has been a Director of the Company since 2013.

Committee: Chairman of the Strategy Committee


Director, Chairman of the Strategy Committee
Prof. Jean-Yves BLAY, MD, PhD

Independent Director, Chairman of the Clinical Development Committee 

Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Léon Bérard Center in Lyon since 2014. He holds a PhD obtained in 1994 from the Claude Bernard University in Lyon and has been authorized to supervise research since 1996. He currently leads the LYriCAN project (integrated cancer research) at the French National Cancer Institute. Former president of the European Organization for Research and Treatment of Cancer, Prof. Jean‑Yves Blay is currently director of the NETSARC network accredited by the French National Cancer Institute and president of the French Sarcoma Group. At international level, he is a faculty member of the ESMO (European Society of Medical Oncology) and the SPH (Scientific Panel for Health).  He has led the European Commission’s Conticanet network and is currently leading the Eurosarc FP7 project. Author of more than 500 international publications, Prof. Jean-Yves Blay advises various national and international research organizations and institutions. His work has been rewarded by several prizes including that of the French National Academy of Medicine, which he joined as a corresponding member in 2014.

Committee: Chairman of the Clinical Development Committee


Independent Director, Chairman of the Clinical Development Committee



Benoît Habert is Executive Vice President and Director of the Marcel Dassault Industrial Group and is a board member of several listed and private companies. He holds an MBA from INSEAD and a Master of Business Law.

Benoît Habert has been a Director of the Company since 2000.

Committees: member of the Compensation Committee and of the Audit Committee




Independent Director, Chairwoman of the Audit Committee

Marie Landel founded Marie Landel & associates, now Axelia Partners, a consultancy based in Cambridge (Massachusetts) specialized in advising European companies on the creation and development of US subsidiaries. She has significant experience supporting French and European biotechnology companies in the United States. With more than 30 years of practice, she has built an extensive network in the financial community focused on this sector. Marie Landel is a French CPA (Expert-comptable), and she holds an MBA from the European Business School (Paris, Frankfurt and London). She also sat on the Boards of TxCell, Safe Orthopaedics and Cellnovo. Chevalier de la Légion d’Honneur et de l’Ordre du Mérite, Marie Landel was also a Foreign Trade Advisor to the French government (CCEF or Conseillers pour le Commerce Extérieur de la France for 10 years). She is now a member of the French Tech Hub in Miami. As a member of Women Initiative Foundation, she coaches Women Entrepreneur.

Marie Landel has been a Director of the Company since 2017.

Committee: Chairwoman of the Audit Committee, member of the ESG Committee


Independent Director, Chairwoman of the Audit Committee
Maya SAID, PhD

Independent Director

Maya Said has been an independent Director of Transgene since 2017. She brings more than 15 years of international experience in the healthcare industry. Previously, she was Vice-President, Senior Global Head of Oncology Policy and Market Access at Novartis, and Vice President, Head of Strategy, Science Policy & External Innovation, Global R&D at Sanofi. Her career started within the HealthCare and Strategy practice of The Boston Consulting Group (BCG). Maya has a PhD in Computer Science & Systems Biology from the Massachusetts Institute of Technology (MIT), as well as two Master’s degrees in Electrical Engineering & Computer Science and in Biology. She has also studied finance and healthcare organizational systems at the Harvard Business School. Maya is the author of more than 20 publications in peer-reviewed journals.

Committees: Chairwoman of the Compensation Committee, member of the Strategy Committee and Clinical Development Committee


Independent Director, Chairwoman of the Compensation committee

Independent Director 

Carol Stuckley brings more than 35 years of experience as a strategic and international financial executive, with proven success leading finance teams and creating shareholder value for healthcare companies. She currently serves as a Board Director and Chairperson of the audit committee of Centessa Pharmaceuticals, plc and previously served on the board of directors of Ipsen (where she chaired the audit committee) and Epizyme, Inc. Carol Stuckley was formerly Chief Financial Officer and Senior Vice President at HPS, which was acquired by TransUnion, Inc. Previously, Carol was Chief Financial Officer, Vice President, Finance at Galderma North America (Nestlé Skin Health S.A.). Carol started her 23-year career at Pfizer Inc., where she held multiple financial roles of increasing responsibility, and was most recently Assistant Treasurer, Vice President, Finance and Corporate Officer of Pfizer Inc. A US citizen, Carol holds a Master of Arts Degree in Economics and an MBA in International Finance from Temple University’s Fox Business School.

Committee: Member of the Audit Committee and of the Compensation Committee


Independent Director

Sandrine Flory

Director, represented by Sandrine FLORY

TSGH SAS has been Transgene’s reference shareholder since 1994. This financial holding company is a member of Institut Mérieux Group and is in fine owned by the Mérieux family and by the Christophe and Rodolphe Mérieux Foundation. Philippe Archinard is CEO of TSGH. Sandrine Flory has been TSGH’s permanent representative on Transgene’s Board of Directors since January 2021.

Sandrine Flory has been Chief Financial Officer of Institut Mérieux since 2020. She has spent 18 years at bioMérieux, in various positions in finance. She was CFO for bioMérieux EMEA from 2014 to 2020. Prior to joining bioMérieux, Sandrine Flory spent 9 years at PriceWaterhouseCoopers in France and Australia. She holds a Master’s degree in Finance and Accounting and a MS in Business Valuation and Transmission from the Université Lyon 2 (France).

The financial holding company TSGH has been a Director of the Company since 2002, Sandrine Flory is its representative since 2021.

Committees: Chairwoman of the ESG Committee, member of the Audit Committee


Director, represented by Sandrine FLORY (Chairwoman of the ESG committee)

Last update : June 2023.